Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.
暂无分享,去创建一个
S. Massry | L. Mccann | H. Malluche | J. Silver | C. Langman | O. Mehls | I. Salusky | J. Coburn | M. Fukagawa | J. McCarthy | K. Martin | G. Coen | K. O̸lgaard | M. Smogorzewski | E. Slatopolsky
[1] S. Ott,et al. Osteoporosis in chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] K. Martin,et al. Parathyroid hormone: new assays, new receptors. , 2004, Seminars in nephrology.
[3] M. Wolf,et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.
[4] D. McCarron,et al. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. , 2003, The New England journal of medicine.
[5] H. Malluche,et al. Interventional Nephrology and Dialysis: Bone Biopsy: Indications, Techniques, and Complications , 2003 .
[6] A. Parfitt. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. , 2003, Current opinion in nephrology and hypertension.
[7] R. Elashoff,et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. , 2003, Kidney international.
[8] H. Malluche,et al. Pth 1-84, Pth fragments and bone turnover. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] M. Monier‐Faugere,et al. Parathyroid hormone assays--evolution and revolutions in the care of dialysis patients. , 2003, Clinical nephrology.
[10] S. Rosansky,et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.
[11] H. Jüppner,et al. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. , 2003, Kidney international.
[12] E. Slatopolsky,et al. Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats , 2002 .
[13] Y. Ohashi,et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] E. Bonucci,et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] P. Raggi,et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.
[16] E. Bonucci,et al. Renal Osteodystrophy in Predialysis and Hemodialysis Patients: Comparison of Histologic Patterns and Diagnostic Predictivity of Intact PTH , 2002, Nephron.
[17] Alex J. Brown,et al. Vitamin D Analogs for the Treatment of Secondary Hyperparathyroidism , 2002, Blood Purification.
[18] K. Martin,et al. Strategies to minimize bone disease in renal failure. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] K. Martin,et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] D. Batlle,et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] H. Malluche,et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. , 2001, Kidney international.
[22] K. Martin,et al. The evolution of assays for parathyroid hormone , 2001, Current opinion in nephrology and hypertension.
[23] Keith C. Norris,et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] K. O̸lgaard,et al. Prevention of uremic bone disease using calcimimetic compounds. , 2001, Annual review of medicine.
[25] Keith C. Norris,et al. Intermittent doxercalciferol (1α-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism , 2000 .
[26] E. González. The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] J. Coburn,et al. Calcimimetic agents and the calcium-sensing receptor. , 2000, Current opinion in nephrology and hypertension.
[28] Burke,et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] A. Dusso,et al. New analogs of vitamin D3. , 1999, Kidney international. Supplement.
[30] I. Salusky,et al. Growth Retardation in Children with Chronic Renal Failure , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] P. Eskildsen,et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. , 1999, Kidney international.
[32] E. Slatopolsky,et al. Vitamin D Analogs: Perspectives for Treatment , 1999, Mineral and Electrolyte Metabolism.
[33] P. Ureña,et al. Circulating biochemical markers of bone remodeling in uremic patients. , 1999, Kidney international.
[34] A. Hutchison. Calcitriol, Lanthanum Carbonate, and Other New Phosphate Binders in the Management of Renal Osteodystrophy , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[35] E. Bonucci,et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] L. Hamm,et al. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] G. Segre,et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. , 1998, Kidney international.
[38] L. Hamm,et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. , 1998, Journal of the American Society of Nephrology : JASN.
[39] Y. Ohashi,et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[40] H. Jüppner,et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. , 1998, Kidney international.
[41] E. Bonucci,et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study , 1996 .
[42] P. Ureña,et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.
[43] D. Sherrard,et al. The aplastic form of renal osteodystrophy. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[44] Mei Wang,et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[45] Y. Pei,et al. Risk factors for renal osteodystrophy: A multivariant analysis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[46] D. Sherrard. Aplastic bone: a nondisease of medical progress. , 1995, Advances in renal replacement therapy.